Michael Gibney from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics		How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology - 28 days ago With patent losses on the horizon, Amgen refocuses its business strategy - about 2 months ago New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach - about 2 months ago AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration - about 2 months ago Cancer vaccines have stumbled, but the approach is gaining new steam - about 2 months ago Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - 2 months ago Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma - 2 months ago Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions - 3 months ago With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 3 months ago Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid - 3 months ago Drugmakers prep for bird flu outbreak, despite continued low risk - 3 months ago By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - 3 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 3 months ago Subcutaneous options offer convenience for patients — and a valuable window for drugmakers - 4 months ago 4 closely watched FDA approval dates in 2025 from J&J, Novo and more - 4 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - 4 months ago Maternal mortality trends remain dire — and researchers face an uphill battle to solve them - 4 months ago Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - 4 months ago GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback. - 4 months ago How Astellas juggles the moving parts of cancer precision medicine development - 5 months ago How Alexion markets a rare disease drug by ‘starting with the end in mind’ - 5 months ago Specialized CROs aim to boost participation among women and other underrepresented groups - 5 months ago How the incoming administration could impact FTC’s approach to pharma M&A - 5 months ago An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 5 months ago Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals - 5 months ago What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine - 5 months ago Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug - 5 months ago Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past - 5 months ago Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in - 6 months ago Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 6 months ago 2024 PharmaVoice 100s: Cancer Care Visionaries - 6 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 6 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 6 months ago How AZ’s respiratory wins are ramping up for a bigger prize in COPD - 6 months ago Why pharma megamergers may become a relic of the past - 6 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 6 months ago With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble - 6 months ago As new Alzheimer’s biomarkers come into play, here’s where the money is going - 6 months ago AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential - 6 months ago Will a Medicare boost propel digital therapeutics to the mainstream? - 6 months ago Flu vaccination rates are falling despite record child deaths. Can innovation save the day? - 7 months ago Top pharma and biotech conferences 2025 - 7 months ago How Lilly’s sustainability goals come face to face with massive growth - 7 months ago A new way of determining a drug’s value — with health equity in mind - 8 months ago Huntington’s disease R&D is regaining ground after several disappointments - 8 months ago Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that. - 8 months ago A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market - 8 months ago Their Alzheimer’s treatment worked — but shares fell anyway - 8 months ago Will the IRA squash new drugs? Those worries are likely exaggerated, studies say. - 8 months ago 23andMe inches closes to cancer immunotherapy, guided by its genetic database - 8 months ago